Fusion Pharmaceuticals Inc.
FUSN · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.24 | -0.30 | 0.05 | -0.00 |
| FCF Yield | -13.59% | -54.73% | -43.48% | -11.93% |
| EV / EBITDA | -6.32 | -1.53 | -1.62 | -5.42 |
| Quality | ||||
| ROIC | -36.55% | -41.97% | -33.99% | -13.13% |
| Gross Margin | 34.96% | -3,931.14% | -3,813.68% | 0.00% |
| Cash Conversion Ratio | 0.86 | 0.84 | 0.93 | 0.38 |
| Growth | ||||
| Revenue 3-Year CAGR | 12.82% | – | – | – |
| Free Cash Flow Growth | -13.62% | 2.35% | -150.02% | -118.37% |
| Safety | ||||
| Net Debt / EBITDA | 0.12 | 0.04 | 0.57 | 2.91 |
| Interest Coverage | -19.21 | -48.88 | 0.00 | -116.01 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -5.97 | 5.43 | 0.11 |
| Cash Conversion Cycle | 239.19 | 352.65 | 143.48 | 639.89 |